<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328925</url>
  </required_header>
  <id_info>
    <org_study_id>RM02-3022</org_study_id>
    <nct_id>NCT01328925</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children</brief_title>
  <official_title>Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romark Laboratories L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Romark Laboratories L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of nitazoxanide suspension
      compared to placebo in treating rotavirus disease in pediatric patients less than 6 years of
      age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from first dose to resolution of symptoms.</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Resolution of all gastrointestinal symptoms associated with viral diarrhea at enrollment including abdominal pain or tenderness, distention, etc. with the patient not requiring anti-motility or other palliative treatment. Symptom resolution must be maintained for at least 48 hours to be considered valid.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from first dose to virologic response</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Daily stool samples will be analyzed by ELISA for the presence of rotavirus. Virologic response is defined by a negative ELISA stool test for rotavirus on 2 consecutive days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from first dose to hospital discharge</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>For hospitalized patients, the study will monitor the time in hours from the first dose of study medication to discharge from the hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of oral rehydration solutions consumed</measure>
    <time_frame>Up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of intravenous rehydration required</measure>
    <time_frame>Up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool weight</measure>
    <time_frame>Up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Rotavirus Infection</condition>
  <condition>Viral Gastroenteritis Due to Rotavirus</condition>
  <arm_group>
    <arm_group_label>Nitazoxanide Oral Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitazoxanide Oral Suspension 100 mg/5 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Suspension</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Nitazoxanide Oral Suspension dose based on age:
Age &lt;12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days</description>
    <arm_group_label>Nitazoxanide Oral Suspension</arm_group_label>
    <arm_group_label>Placebo Oral Suspension</arm_group_label>
    <other_name>Alinia</other_name>
    <other_name>NTZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt; 6 years.

          -  Patients with diarrhea (defined as 3 or more liquid stools per day).

          -  Stool positive for rotavirus by ELISA.

        Exclusion Criteria:

          -  Other identified causes of diarrhea at screening (pathogenic protozoa, bacteria,
             viruses or lactose intolerance).

          -  Serious systemic disorders incompatible with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Abu-Zekry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo University Children's Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <last_update_submitted>April 1, 2011</last_update_submitted>
  <last_update_submitted_qc>April 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Celine Rossignol, MS</name_title>
    <organization>Romark Laboratories, L.C.</organization>
  </responsible_party>
  <keyword>Rotavirus</keyword>
  <keyword>Viral gastroenteritis</keyword>
  <keyword>Gastroenteritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Rotavirus Infections</mesh_term>
    <mesh_term>Enteritis</mesh_term>
    <mesh_term>Adenovirus Infections, Human</mesh_term>
    <mesh_term>Enterovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

